Drug class
Mitogen-activated protein kinase kinase (MEK1/2) inhibitor; targeted antineoplastic
Mechanism of action
Reversibly inhibits MEK1 and MEK2, kinases in the RAS–RAF–MEK–ERK pathway, reducing downstream ERK signalling and proliferation of tumour cells with pathway-activating BRAF mutations.
General use cases
- In combination with encorafenib for treatment of adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation under the US product indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
